Actinium Pharmaceuticals, Inc. announced that three abstracts detailing results from the completed Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) have been accepted for presentation at the 65(th) Annual American Society of Hematology Annual Meeting & Exposition (ASH) being held in San Diego on December 9-12, 2023. Outcomes of patients with a TP53 gene mutation enrolled in the SIERRA trial have been accepted for an oral presentation and results detailed in the abstract include the following: Medn OvOverall Survival (OS) of TP53 positive patients receiving Iob-B and a bone marrow transplant (BMT) w was 5.49 months compared to 1.66 months in patients who did not receive Iomab-B; Iomab-B produced a statistically significant improvement in median OS in TP53 positive patients with a hazard ratio of 0.23 and p-value of 0.0002; Median OS of 6.37 months in TP53 negative patients receiving Iomab-B and 5.72 months for TP53 positive patients demonstrating Iomab-B's mutation agnostic mechanism and ability to overcome TP53 gene mutations; 24% of patients (37/153) enrolled on the SIERRA trial had a TP53 mutation, with 17 being randomized to the Iomab-B arm and 20 randomized to the control arm.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.77 USD | +0.41% | +9.78% | +92.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.32% | 293M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.23% | 22.28B | |
-5.61% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- ATNM Stock
- News Actinium Pharmaceuticals, Inc.
- Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting